Passive amylin immunotherapy improves brain function and reduces brain β‐amyloid pathology in APP/PS1 mice
These findings suggest that passive amylin immunotherapy is well-tolerated in APP/PS1 mice and does not induce microhemorrhages or other adverse effects, supporting its safety for further investigation in HuAmy-APP/PS1 mice.
Authors
- Florin Despa (ORCID: https://orcid.org/0000-0002-5879-6449)
- Deepak Kotiya (ORCID: https://orcid.org/0000-0001-5794-8626)
Institutions
- University of Kentucky (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70855_106792
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00